PHILADELPHIA, November 7, 2018 /PRNewswire/ --
Via Oncology customers can opt to have both Via Pathways and NCCN Guidelines decision support
Elsevier, the information analytics business specializing in science and health, will integrate the National Comprehensive Cancer Network's NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and utilize the NCCN Chemotherapy Order Templates (NCCN Templates®) as a reference into Via Oncology's Via Portal to provide clinical decision support at point of care and NCCN Guidelines® concordance reporting. The NCCN Guidelines will also be used as a reference resource for developing and maintaining the Via Pathways.
(Logo: https://mma.prnewswire.com/media/754760/Elsevier_Logo.jpg )
Beginning in 2019, the Via Portal will be enhanced to include drugs and biologics recommendations from the NCCN Guidelines for use when providers are going off pathway. The Via Portal will ultimately include 34 NCCN Guidelines support for all Via Pathways diseases for Medical Oncology.
"NCCN is pleased to collaborate with Elsevier and Via Oncology to enhance the Via Pathways with the NCCN Guidelines," said Robert W. Carlson, MD, Chief Executive Officer, NCCN. "In supporting this agreement, both NCCN and Elsevier recognize the value of having evidence-based NCCN Guidelines recommendations at the point of care facilitated through technology to achieve the best outcomes for patients with cancer."
The NCCN Guidelines are the recognized standard for clinical and policy decisions in cancer care and are the most thorough and most frequently updated clinical practice guidelines available in any area of medicine. Derived directly from the NCCN Guidelines, the NCCN Templates include chemotherapy and immunotherapy regimens with literature support, supportive care agents, monitoring parameters and safety instructions. The goal of the NCCN Templates is to enhance patient safety by empowering health care providers to standardize patient care, reduce medical errors, and anticipate and manage adverse events.
"We are pleased to be working with NCCN to strengthen our product for oncologists and patients with cancer," said Dr. John Danaher, President of Clinical Solutions, Elsevier. "When oncologists decide to divert from the generally accepted pathway because of their patient's unique need, the Via Portal will provide additional decision support for assuring that the care plan matches up with the NCCN Guidelines and can be measured and tracked."
Via Oncology helps cancer centers demonstrate the value of their care to patients, referring physicians and payers, by developing and implementing clinical pathways in collaboration with its network of more than 2,000 US cancer care providers. Via Oncology's Via Pathways includes evidence-based proprietary content developed by committees composed of leading oncologists that forms the basis of clinical algorithms covering 95 percent of cancer types treated in the US.
The Via Pathways are deployed to physicians and their staff at the point of care through the Via Portal, a patient-specific decision support tool that is integrated with the electronic medical record and provides seamless measurement of adherence. Via Pathways addresses more than 2,000 unique patient presentations, including expert-defined clinical algorithms and specific recommendations for all significant aspects of cancer care.
About the National Comprehensive Cancer Network
The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 27 leading cancer centers devoted to patient care, research, and education, is dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers.
Clinicians, visit NCCN.org. Patients and caregivers, visit NCCN.org/patients. Media, visit NCCN.org/news. Follow NCCN on Twitter @NCCNnews and Facebook @National.Comprehensive.Cancer.Network
About Elsevier
Elsevier is a global information analytics business that helps institutions and professionals advance healthcare, open science and improve performance for the benefit of humanity. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support and professional education, including ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, 38,000 e-book titles and many iconic reference works, including Gray's Anatomy. Elsevier is part of RELX Group, a global provider of information and analytics for professionals and business customers across industries. www.elsevier.com
Media contact
Rachel Darwin, Public Relations Manager NCCN +1-267-622-6624 [email protected]
Christopher Capot, Global Communications Elsevier +1-917-704-5174 [email protected]
SOURCE Elsevier
Advertisement
Via Oncology customers can opt to have both Via Pathways and NCCN Guidelines decision support
Elsevier, the information analytics business specializing in science and health, will integrate the National Comprehensive Cancer Network's NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and utilize the NCCN Chemotherapy Order Templates (NCCN Templates®) as a reference into Via Oncology's Via Portal to provide clinical decision support at point of care and NCCN Guidelines® concordance reporting. The NCCN Guidelines will also be used as a reference resource for developing and maintaining the Via Pathways.
Advertisement
(Logo: https://mma.prnewswire.com/media/754760/Elsevier_Logo.jpg )
Beginning in 2019, the Via Portal will be enhanced to include drugs and biologics recommendations from the NCCN Guidelines for use when providers are going off pathway. The Via Portal will ultimately include 34 NCCN Guidelines support for all Via Pathways diseases for Medical Oncology.
"NCCN is pleased to collaborate with Elsevier and Via Oncology to enhance the Via Pathways with the NCCN Guidelines," said Robert W. Carlson, MD, Chief Executive Officer, NCCN. "In supporting this agreement, both NCCN and Elsevier recognize the value of having evidence-based NCCN Guidelines recommendations at the point of care facilitated through technology to achieve the best outcomes for patients with cancer."
The NCCN Guidelines are the recognized standard for clinical and policy decisions in cancer care and are the most thorough and most frequently updated clinical practice guidelines available in any area of medicine. Derived directly from the NCCN Guidelines, the NCCN Templates include chemotherapy and immunotherapy regimens with literature support, supportive care agents, monitoring parameters and safety instructions. The goal of the NCCN Templates is to enhance patient safety by empowering health care providers to standardize patient care, reduce medical errors, and anticipate and manage adverse events.
"We are pleased to be working with NCCN to strengthen our product for oncologists and patients with cancer," said Dr. John Danaher, President of Clinical Solutions, Elsevier. "When oncologists decide to divert from the generally accepted pathway because of their patient's unique need, the Via Portal will provide additional decision support for assuring that the care plan matches up with the NCCN Guidelines and can be measured and tracked."
Via Oncology helps cancer centers demonstrate the value of their care to patients, referring physicians and payers, by developing and implementing clinical pathways in collaboration with its network of more than 2,000 US cancer care providers. Via Oncology's Via Pathways includes evidence-based proprietary content developed by committees composed of leading oncologists that forms the basis of clinical algorithms covering 95 percent of cancer types treated in the US.
The Via Pathways are deployed to physicians and their staff at the point of care through the Via Portal, a patient-specific decision support tool that is integrated with the electronic medical record and provides seamless measurement of adherence. Via Pathways addresses more than 2,000 unique patient presentations, including expert-defined clinical algorithms and specific recommendations for all significant aspects of cancer care.
About the National Comprehensive Cancer Network
The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 27 leading cancer centers devoted to patient care, research, and education, is dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers.
Clinicians, visit NCCN.org. Patients and caregivers, visit NCCN.org/patients. Media, visit NCCN.org/news. Follow NCCN on Twitter @NCCNnews and Facebook @National.Comprehensive.Cancer.Network
About Elsevier
Elsevier is a global information analytics business that helps institutions and professionals advance healthcare, open science and improve performance for the benefit of humanity. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support and professional education, including ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, 38,000 e-book titles and many iconic reference works, including Gray's Anatomy. Elsevier is part of RELX Group, a global provider of information and analytics for professionals and business customers across industries. www.elsevier.com
Media contact
Rachel Darwin, Public Relations Manager NCCN +1-267-622-6624 [email protected]
Christopher Capot, Global Communications Elsevier +1-917-704-5174 [email protected]
SOURCE Elsevier
